Interstitial Lung Disease (ILD)

Interstitial lung disease (ILD) refers to a group of chronic lung disorders that cause inflammation and scarring (fibrosis) of the lung tissue. This scarring makes it difficult for oxygen to pass into the bloodstream, leading to shortness of breath and a dry cough that gradually worsens over time.

ILD can result from autoimmune diseases, environmental exposures, or unknown causes such as idiopathic pulmonary fibrosis (IPF). Other forms include sarcoidosis and hypersensitivity pneumonitis.

At The Medical Group of New Jersey, our pulmonologists provide comprehensive ILD care, including advanced imaging, lung function testing, and biopsy when needed, followed by individualized treatment focused on slowing disease progression, managing symptoms, and improving quality of life.

Symptom Onset & Initial Evaluation

Symptoms of ILD usually develop gradually but can become persistent and progressive over months to years. Patients often notice:

• Shortness of breath during daily activity or exercise
• Dry, hacking cough that does not produce mucus
• Fatigue or reduced endurance
• Unexplained weight loss

During your first visit, your pulmonologist will take a detailed history, reviewing medications, environmental or occupational exposures (such as dust or mold), and any autoimmune or connective tissue disorders. A physical exam often reveals crackling sounds in the lungs and signs of low oxygen levels.

Diagnosis

Diagnosing ILD requires a combination of imaging, pulmonary testing, and sometimes tissue sampling to determine the exact cause.

Your evaluation may include:

• High-resolution CT (HRCT) scan: Provides detailed images of lung scarring or inflammation
• Pulmonary function tests (PFTs): Measure how much air the lungs can hold and how efficiently oxygen is exchanged
• Blood work: Detects autoimmune markers or inflammatory conditions
• Lung biopsy (surgical or bronchoscopic): May be performed to confirm the type of ILD

At The Medical Group of New Jersey, these diagnostic steps are coordinated seamlessly by a multidisciplinary team of pulmonologists, radiologists, and pathologists to ensure accurate classification and treatment planning.

Treatment

While scarring from ILD cannot be reversed, early and targeted treatment can help slow disease progression and relieve symptoms.

Medication Management

• Antifibrotic medications (nintedanib, pirfenidone): Slow lung scarring in idiopathic pulmonary fibrosis¹
• Corticosteroids or immunosuppressants: Used in inflammatory or autoimmune-related ILD
• Oxygen therapy: Improves energy levels and reduces shortness of breath

Lifestyle & Supportive Care

• Pulmonary rehabilitation: Enhances breathing efficiency and stamina
• Vaccinations: Protect against respiratory infections like flu and pneumonia
• Smoking cessation and exposure control: Reduce lung irritation and further damage

Advanced Options

• For severe or end-stage cases, your pulmonologist may discuss lung transplant evaluation at a partnering transplant center.

1. Yang, Mei, et al. “Efficacy and Safety of Antifibrotic Agents in the Treatment of CTD-ILD and RA-ILD: A Systematic Review and Meta-Analysis.” Respiratory Medicine, vol. 216, 1 Sept. 2023, p. 107329.

Ongoing Management & Prevention

ILD requires close monitoring to adjust therapy and manage symptoms as the disease evolves. At The Medical Group of New Jersey, ongoing care includes:

• Routine pulmonary function and oxygen testing
• Medication review and side-effect monitoring
• Nutritional and physical therapy support
• Emotional support and palliative care when needed

With early diagnosis and comprehensive care, many patients maintain stable lung function and good quality of life for years.